Clinical Trials Browser

Transurethral Resection of Bladder × 1 year × Clear all

NCT02792582 2026-04-17

A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection

Phase 2 Active not recruiting

Brain Neoplasms, Craniopharyngioma

NCT06980038 2026-04-16

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Laryngeal Neoplasms, Mouth Neoplasms

NCT06172296 2026-04-14

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

Phase 3 Recruiting

Neuroblastoma, Ganglioneuroblastoma

NCT06805305 2026-04-14

DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)

Phase 2 Recruiting

Glioblastoma

NCT07288112 2026-04-14

DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma

Phase 1/2 Recruiting

Melanoma

NCT03775265 2026-04-13

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT04164082 2026-04-13

Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Phase 2 Active not recruiting

Urinary Bladder Neoplasms

NCT07061964 2026-04-13

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT07468136 2026-04-13

Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas

Phase 1/2 Not yet recruiting

Astrocytoma, Glioblastoma, Glioma, Lymphoma, Follicular, Oligodendroglioma

NCT07000084 2026-04-07

GAIN-BCG

Phase 3 Recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT06914479 2026-03-11

Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors

Phase 1 Recruiting

Brain Neoplasms

NCT06470282 2026-02-18

Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer

Phase 1/2 Recruiting

Urinary Bladder Neoplasms

NCT05521698 2026-02-17

Study to Determine Possible Effects of Apalutamide, Compared to Placebo, on EGFR Expression in Patients With Non-muscle Invasive Bladder Cancer

Phase 1 Not yet recruiting

Non-Muscle Invasive Bladder Urothelial Carcinoma

NCT04221503 2026-01-08

Niraparib/TTFields in GBM

Phase 2 Active not recruiting

Glioblastoma

NCT07227961 2025-11-13

PROMIS and Mobility Evaluation in Sarcoma Patients

Alzheimer Disease, Sarcoma, Giant Cell Tumor of Bone

NCT02621151 2025-10-07

Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder

Phase 2 Active not recruiting

60 enrolled 11 charts

Muscle-invasive Urothelial Cancer of the Bladder

NCT06338657 2025-09-16

FID-007 Followed by Standard of Care Surgery in Head and Neck Cancer

Phase 1 Terminated

Squamous Cell Carcinoma of Head and Neck

NCT06629233 2025-08-29

Tn-Miner

Phase NA Enrolling by invitation

Estrogen Receptor Positive Breast Cancer

NCT06537154 2025-07-30

NEO-BLAST

Phase 2/3 Recruiting

Urinary Bladder Neoplasms

NCT07067749 2025-07-24

TEMPO-MIBC

Phase 3 Recruiting

Urinary Bladder Neoplasms, Neoplasms